Clinical Applications of Molecular Biomarkers in Prostate Cancer
Felipe Couñago, Fernando López‐Campos, Ana Aurora Díaz-Gavela, Elena Almagro, Esaú Fernández‐Pascual, I. Henrı́quez, Rebeca Lozano, Estefanía Linares, Alfonso Gómez‐Iturriaga, Guillermo de Velasco, Luis Miguel Quintana Franco, Ignacio Rodríguez-Melcón, J. López Torrecilla, Daniel E. Spratt, Luis Leonardo Guerrero, Juan Ignacio Martínez‐Salamanca, Elia del Cerro
Abstract
There is clinically relevant molecular heterogeneity in prostate cancer (PCa), but this biological diversity has had only a minimal impact on clinical practice. Treatment outcomes in patients with localised PCa are often highly variable, even among patients stratified to the same risk group or disease state based on standard clinical and pathological parameters. In recent years, the development of gene panels has provided valuable data on the differential expression of genes in patients with PCa. Nevertheless, there is an urgent need to identify and validate prognostic and predictive biomarkers that can be applied across clinical scenarios, ranging from localised disease to metastatic castration-resistant PCa. The availability of such tools would allow for precision medicine to finally reach PCa patients. In this review, we evaluate current data on molecular biomarkers for PCa, with an emphasis on the biomarkers and gene panels with the most robust evidence to support their application in routine clinical practice.